19th & 20th Oct 2015
Holiday Inn Regents Park, London UK
www.copd-conference.co.uk
Sponsored by Quintiles
 

 

3HRS + OF VALUABLE NETWORKING

18 THOUGHT PROVOKING PRESENTATIONS + 1 EXCLUSIVE QUINTILES WORKSHOP
SPEAKERS INCLUDE NOVARTIS, VERONA, MUNDIPHARMA, JANSSEN, MEDIMMUNE, CHIESI
NOW RUNNING FOR ALMOST A DECADE – 7 YEARS OF COPD EXPERTISE


Now in its 7th year, COPD 2015 will look to provide the industry with a niche platform for discussion and a forum to learn from market led case studies and key note addresses delivered through five compelling sessions.

Scope of conference

SESSION 1.    DRUG DEVELOPMENT AND COMBINATIONAL THERAPIES :

Gain insight into formulation developments and the manufacturing of dry powder inhalation products through a keynote address delivered by Novartis’s Operational Lead in Inhalation and New Solids, Dr Frank Thielmann. The role of immunology, protein kinase pathways and novel therapeutic agents will also be discussed by Imperial College London, the National Heart & Lung Institute and the University of Basque respectively. Strategic guidance on combination therapy will be given by Teva and Prosonix, plus Verona Pharma CEO, Jan Anders-Karlsson, provides an exclusive address on their “first in class” inhaled COPD Drug.

SESSION 2.   DEVELOPING CLINICAL TRIALS FOR COPD :

Novartis COPD Medical Director, Dr Konstantinos Kostikas ascertains the ACOS Definition and explains the characteristics of a grey-zone syndrome which is currently excluded from asthma and COPD trials. In this session, key topics on endpoint in clinical trials, patient selection, recruitment and effective rehabilitation will also be covered by Mundipharma, University hospital Geneva and Respiratory Research Clinical Trials.

SESSION 3.    DEFINING COPD PULMONARY INDICATIONS THROUGH BIOMARKERS :

Glyconics Limited open the session with an update on hand held device for biomarker selection which uses ground breaking technology in respiratory clinical diagnostics. This will be followed by a Janssen case study on the ADEPT Trial which will discuss personalised medicine and biomarker assessment.

SESSION 4.    COPD CO-MORBIDITIES :

This spotlight will ask questions such as: What is this link between co-morbidities and disease? What current issues do co-morbidities present with COPD treatment? Do corticosteroids cause more harm than good?

SESSION 5.    MANAGING EXACERBATIONS :

An update on the clinical management of exacerbations will be given by  Chiesi Chief Medical Officer and Director of Global Clinical Development, Stefano Petruzzelli. With additional presentations from University Hospital Genevaand MedImmune, the final session will address pulmonary rehabilitation, non-invasive ventilation and will investigate the role if ectopic lymphoid follicles in respiratory disease.

Closing remarks:

The conference closes with a host nation addresses presented by the British Lung Foundation. Noell Snell, Director of Research, evaluates the current state of UK respiratory research, its future outlook, and its strategy in partnership with patients.

Download a brochure before registering HERE or make an enquiry

How to register:

Register your place online at www.copd-conference.co.uk

For bespoke sponsorship packages contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For delegate enquires, contact Tommy King on +44 (0)20 7827 6052 or email tking@smi-online.co.uk